CD274 and mesenchymal cell neoplasm: This suggests a complex therapeutic implication: mesenchymal tumors with low miR-200 expression may, despite their poor prognosis, be preferentially responsive to PD-1/PD-L1 blockade due to high baseline PD-L1 levels.